Click [...] To view or add a comment, sign in $NVO has started a Phase 1 trial for its new obesity drug candidate LX9851, developed with Lexicon Pharmaceuticals The drug is oral and works differently from current GLP-1 treatments, targeting fat metabolism and satiety signals The study will assess safety in overweight and obese patients, with results expected in Q1 2027 Lexicon receives a $10M milestone payment and could earn up to $1B plus royalties if successful #stocks #Investing To view or add a comment, sign in 16,852 followers
She points out that many people are taking compounded versions of Zepbound, Wegovy and other GLP-1s, but the compounding pharmacies started making these after the drugs had gone through trials and been approved by the FDA
Another key part of patient education is setting realistic expectations about weight loss
Peptides are short chains of amino acidstypically between 2 and 50 amino acids linked togetherthat function as signaling molecules throughout the body
Hyaluronic Acid Injections: Hyaluronic acid injections improve joint lubrication and reduce friction in degenerative conditions (knee osteoarthritis)
It typically affects the ophthalmic branch (V1)
